Relmada Therapeutics, Inc. RLMD Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s change in accrued liabilities?
- Relmada Therapeutics, Inc. (RLMD) reported change in accrued liabilities of -$1.56M in Q1 2026.
- How has Relmada Therapeutics, Inc.'s change in accrued liabilities changed year-over-year?
- Relmada Therapeutics, Inc.'s change in accrued liabilities increased by 28.9% year-over-year, from -$2.19M to -$1.56M.
- What does change in accrued liabilities mean?
- Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.